Eli Lilly Raises 2024 Outlook Again as Zepbound Sales Surge on Weight-Loss Drug Demand

Eli Lilly has raised its full-year financial guidance for the third time this year, driven by soaring sales of its weight-loss and diabetes drug Zepbound. The company now expects stronger revenue and earnings, reflecting the continued dominance of its GLP-1 treatment in the highly competitive U.S. prescription weight-loss market. Zepbound, which contains the same active ingredient as Lilly's diabetes drug Mounjaro, has quickly become a blockbuster product since its approval, with demand outstripping supply throughout 2024. The latest outlook increase signals management's confidence in overcoming manufacturing bottlenecks and capturing a larger share of the obesity care market, which analysts estimate could exceed $100 billion annually by 2030. For patients and investors, the news underscores the transformative impact of GLP-1 drugs on healthcare and the economy, as companies like Lilly and rival Novo Nordisk race to expand production capacity. Looking ahead, Lilly's ability to meet surging demand and fend off emerging competitors will be critical to sustaining this momentum.